{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Infection+Control&page=4",
    "query": {
      "intervention": "Infection Control",
      "page": 4
    },
    "page_size": 10
  },
  "pagination": {
    "page": 4,
    "page_size": 10,
    "total_count": 1465,
    "total_pages": 147,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Infection+Control&page=5&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Infection+Control&page=3&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-21T18:04:10.284Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05127525",
      "title": "EffiCacy, Safety and ToLErability of a Novel Ocular ANtiseptic for Ocular Use (CLEAN)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetic Macular Edema",
        "Branch Retinal Vein Occlusion",
        "Glaucoma/Closed Angle Glaucoma"
      ],
      "interventions": [
        {
          "name": "IRX-101",
          "type": "DRUG"
        },
        {
          "name": "Control",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "iRenix Medical, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 5,
      "start_date": "2021-11-15",
      "completion_date": "2022-01-31",
      "has_results": false,
      "last_update_posted_date": "2022-05-24",
      "last_synced_at": "2026-10-21T18:04:10.284Z",
      "location_count": 1,
      "location_summary": "Tampa, Florida",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05127525"
    },
    {
      "nct_id": "NCT06253806",
      "title": "Stellate Ganglion Block for COVID-induced Parosmia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "COVID-19-Induced Parosmia"
      ],
      "interventions": [
        {
          "name": "Stellate Ganglion Block",
          "type": "DRUG"
        },
        {
          "name": "Placebo Sham Injection",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 48,
      "start_date": "2023-10-25",
      "completion_date": "2024-09-16",
      "has_results": true,
      "last_update_posted_date": "2025-11-10",
      "last_synced_at": "2026-10-21T18:04:10.284Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06253806"
    },
    {
      "nct_id": "NCT04480333",
      "title": "Safety, Tolerability and Pharmacokinetics of Inhaled Nanoparticle Formulation of Remdesivir (GS-5734) and NA-831",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Covid19",
        "Corona Virus Infection",
        "Severe Acute Respiratory Syndrome",
        "Severe Acute Respiratory Infection",
        "Severe Acute Respiratory Syndrome (SARS) Pneumonia",
        "Severe Acute Respiratory Syndrome of Upper Respiratory Tract",
        "Neurodegeneration",
        "Neuroinflammatory Response"
      ],
      "interventions": [
        {
          "name": "Drug: NA-831 - 0.10 mg/kg",
          "type": "DRUG"
        },
        {
          "name": "Placebo- 0.10 mg/kg",
          "type": "DRUG"
        },
        {
          "name": "Drug: NA-831 - 0.20 mg/kg",
          "type": "DRUG"
        },
        {
          "name": "Placebo- 0.20 mg/kg",
          "type": "DRUG"
        },
        {
          "name": "Drug: GS-5734 - 1.00 mg/kg",
          "type": "DRUG"
        },
        {
          "name": "Placebo- 1.00 mg/kg",
          "type": "DRUG"
        },
        {
          "name": "Drug: GS-5734 - 2.00 mg/kg",
          "type": "DRUG"
        },
        {
          "name": "Placebo- 2.00 mg/kg",
          "type": "DRUG"
        },
        {
          "name": "Drugs: NA-831 (0.10 mg/kg) plus GS-5734 (1.00 mg/kg)",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Placebo 0.10 mg + 1.00 mg/kg",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Drugs: NA-831 (0.20 mg/kg) plus GS-5734 (2.00 mg/kg)",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Placebo 0.20 mg + 2.00 mg/kg",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "DRUG",
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "Biomed Industries, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "21 Years to 50 Years"
      },
      "enrollment_count": 45,
      "start_date": "2020-09-15",
      "completion_date": "2021-03-31",
      "has_results": false,
      "last_update_posted_date": "2020-07-21",
      "last_synced_at": "2026-10-21T18:04:10.284Z",
      "location_count": 1,
      "location_summary": "Sunnyvale, California",
      "locations": [
        {
          "city": "Sunnyvale",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04480333"
    },
    {
      "nct_id": "NCT03230838",
      "title": "MK-7625A Versus Meropenem in Pediatric Participants With Complicated Urinary Tract Infection (cUTI) (MK-7625A-034)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Complicated Urinary Tract Infection",
        "Pyelonephritis"
      ],
      "interventions": [
        {
          "name": "Ceftolozane/Tazobactam",
          "type": "DRUG"
        },
        {
          "name": "Meropenem",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "7 Days",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "7 Days to 17 Years"
      },
      "enrollment_count": 134,
      "start_date": "2018-04-26",
      "completion_date": "2020-12-03",
      "has_results": true,
      "last_update_posted_date": "2023-05-06",
      "last_synced_at": "2026-10-21T18:04:10.284Z",
      "location_count": 9,
      "location_summary": "Los Angeles, California • Orange, California • San Diego, California + 6 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Baton Rouge",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03230838"
    },
    {
      "nct_id": "NCT05105048",
      "title": "A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Cytomegalovirus (CMV) Vaccine mRNA-1647",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cytomegalovirus Infection"
      ],
      "interventions": [
        {
          "name": "mRNA-1647",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "ModernaTX, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "18 Years to 40 Years"
      },
      "enrollment_count": 9,
      "start_date": "2021-11-08",
      "completion_date": "2023-08-10",
      "has_results": false,
      "last_update_posted_date": "2023-09-11",
      "last_synced_at": "2026-10-21T18:04:10.284Z",
      "location_count": 3,
      "location_summary": "North Hollywood, California • San Diego, California • Honolulu, Hawaii",
      "locations": [
        {
          "city": "North Hollywood",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Honolulu",
          "state": "Hawaii"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05105048"
    },
    {
      "nct_id": "NCT04831840",
      "title": "Recurrent Urinary Tract Infections and the Microbiome",
      "overall_status": "TERMINATED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Recurrent Urinary Tract Infection"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "University of Miami",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "90 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 90 Years · Female only"
      },
      "enrollment_count": 32,
      "start_date": "2021-05-26",
      "completion_date": "2023-11-20",
      "has_results": false,
      "last_update_posted_date": "2024-05-21",
      "last_synced_at": "2026-10-21T18:04:10.284Z",
      "location_count": 2,
      "location_summary": "Fort Lauderdale, Florida • Miami, Florida",
      "locations": [
        {
          "city": "Fort Lauderdale",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04831840"
    },
    {
      "nct_id": "NCT05867017",
      "title": "Long-Term Sequelae of SARS-COV-2 Infection: Diabetes Mellitus",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "COVID-19",
        "Diabete Mellitus"
      ],
      "interventions": [
        {
          "name": "Measure of physiologic parameters",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "The University of Texas Health Science Center at San Antonio",
      "sponsor_class": "OTHER",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 23,
      "start_date": "2023-07-10",
      "completion_date": "2025-11-30",
      "has_results": false,
      "last_update_posted_date": "2026-01-07",
      "last_synced_at": "2026-10-21T18:04:10.284Z",
      "location_count": 1,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05867017"
    },
    {
      "nct_id": "NCT04350138",
      "title": "Safety and Efficacy Study of Meningococcal Group B Vaccine rMenB+OMV NZ (Bexsero) to Prevent Gonococcal Infection",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Gonococcal Infection"
      ],
      "interventions": [
        {
          "name": "Meningococcal Group B Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 2606,
      "start_date": "2020-12-29",
      "completion_date": "2026-07-08",
      "has_results": false,
      "last_update_posted_date": "2026-07-24",
      "last_synced_at": "2026-10-21T18:04:10.284Z",
      "location_count": 10,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • San Francisco, California + 6 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04350138"
    },
    {
      "nct_id": "NCT01546818",
      "title": "Safety and Immune Response Assessment Study of Killed-whole HIV-1 Vaccine (SAV001-H) in Chronic HIV-1 Infected Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "SAV001-H",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Sumagen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 33,
      "start_date": "2012-03",
      "completion_date": "2013-09",
      "has_results": false,
      "last_update_posted_date": "2013-09-09",
      "last_synced_at": "2026-10-21T18:04:10.284Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01546818"
    },
    {
      "nct_id": "NCT05471726",
      "title": "Improving Post-discharge Antimicrobial Use",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Infections"
      ],
      "interventions": [
        {
          "name": "Prospective audit-and-feedback",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Iowa City Veterans Affairs Medical Center",
      "sponsor_class": "FED",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 10,
      "start_date": "2023-05-22",
      "completion_date": "2024-09-09",
      "has_results": false,
      "last_update_posted_date": "2024-10-08",
      "last_synced_at": "2026-10-21T18:04:10.284Z",
      "location_count": 5,
      "location_summary": "Indianapolis, Indiana • Iowa City, Iowa • Baltimore, Maryland + 2 more",
      "locations": [
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05471726"
    }
  ]
}